[1] 孙惠川, 谢青, 荚卫东, 等. 肝癌转化治疗中国专家共识(2021版)[J]. 中国实用外科杂志, 2021, 41(6): 618-632.
[2] 肖永胜, 郭磊, 周俭. 原发性肝癌新辅助治疗进展[J]. 腹部外科, 2021, 34(1): 1-3, 9.
[3] ZHANG Z F, LUO Y J, LU Q, et al.Conversion therapy and suitable timing for subsequent salvage surgery for initially unresectable hepatocellular carcinoma: What is new?[J]. World J Clin Cases, 2018, 6(9): 259-273.
[4] 周俭, 彭远飞, 王征. 余肝不足肝癌手术治疗争议与共识[J]. 中国实用外科杂志, 2018, 38(2): 126-132.
[5] HAMAOKA M, KOBAYASHI T, KURODA S, et al.Hepatectomy after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy: A retrospective cohort study[J]. Int J Surg, 2017, 44: 223-228.
[6] CHONG J U, CHOI G H, HAN D H, et al.Downstaging with Localized Concurrent Chemoradiotherapy Can Identify Optimal Surgical Candidates in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus[J]. Ann Surg Oncol, 2018, 25(11): 3308-3315.
[7] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J/CD]. 肝癌电子杂志, 2020, 7(1): 5-23.
[8] 夏永祥, 张峰, 李相成, 等. 原发性肝癌10 966例外科治疗分析[J]. 中华外科杂志, 2021, 59(1): E003-E003.
[9] AKATEH C, BLACK S M, CONTEH L, et al.Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma[J]. World J Gastroenterol, 2019, 25(28): 3704-3721.
[10] ZHANG T, ZHANG L, XU Y, et al.Neoadjuvant therapy and immunotherapy strategies for hepatocellular carcinoma[J]. Am J Cancer Res, 2020, 10(6): 1658-1667.
[11] 中国医师协会外科医师分会, 中华医学会外科分会胃肠外科学组, 中华医学会外科分会结直肠外科学组, 等. 中国结直肠癌肝转移诊断和综合治疗指南(2020版)[J]. 临床肝胆病杂志, 2021, 37(3): 543-553.
[12] 袁声贤, 周伟平. 原发性肝癌综合治疗的进展和热点[J]. 中华消化外科杂志, 2021, 20(2): 163-170.
[13] WEN T, JIN C, FACCIORUSSO A, et al.Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus[J]. Hepatobiliary Surg Nutr, 2018, 7(5): 353-371.
[14] SU Y Y, LI C C, LIN Y J, et al.Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives[J]. Semin Liver Dis, 2021, 41(3): 263-276.
[15] SI T, CHEN Y, MA D, et al.Preoperative transarterial chemoembolization for resectable hepatocellular carcinoma in Asia area: a meta-analysis of random controlled trials[J]. Scand J Gastroenterol, 2016, 51(12): 1512-1519.
[16] JIANYONG L, JINJING Z, WENTAO W, et al.Preoperative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma: a single center analysis[J]. Ann Hepatol, 2014, 13(4): 394-402.
[17] SHI H Y, WANG S N, WANG S C, et al.Preoperative transarterial chemoembolization and resection for hepatocellular carcinoma: a nationwide Taiwan database analysis of long-term outcome predictors[J]. J Surg Oncol, 2014, 109(5): 487-493.
[18] QI X, LIU L, WANG D, et al.Hepatic resection alone versus in combination with pre- and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis[J]. Oncotarget, 2015, 6(34): 36838-36859.
[19] 中国抗癌协会肝癌专业委员会. 肝动脉灌注化疗治疗肝细胞癌中国专家共识(2021版)[J]. 中华消化外科杂志, 2021, 20(7): 754-759.
[20] LI S H, ZHONG C, LI Q, et al.Neoadjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: An interim analysis of a multi-center, phase 3, randomized, controlled clinical trial[J]. J Clin Oncol, 2021, 39(15 suppl): 4008.
[21] TSUTSUI R, NAGAMATSU H, ITANO O, et al.Neoadjuvant hepatic arterial infusion chemotherapy for resectable hepatocellular carcinomas[J]. 肝癌研究: 英文版, 2018, 4(5): 1-11.
[22] WEI X, JIANG Y, ZHANG X, et al.Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study[J]. J Clin Oncol, 2019, 37(24): 2141-2151.
[23] LUO Z W, CHE X, CAI J Q, et al.Neoadjuvant radiotherapy to improve overall survival in resectable hepatocellular carcinoma[J]. J Clin Oncol, 2021, 39(15 suppl): e16178.
[24] LIN H, LI X, LIU Y, et al.Neoadjuvant radiotherapy provided survival benefit compared to adjuvant radiotherapy for hepatocellular carcinoma[J]. ANZ J Surg, 2018, 88(10): E718-E724.
[25] XIA Y, WANG P, PU L, et al.Preliminary efficacy and safety of perioperative treatment of camrelizumab combined with apatinib in resectable hepatocellular carcinoma (HCC): A prospective phase Ⅱ study[J]. J Clin Oncol, 39(15 suppl): 4082.
[26] YARCHOAN M, ZHU Q, DURHAM J N, et al.Feasibility and efficacy of neoadjuvant cabozantinib and nivolumab in patients with borderline resectable or locally advanced hepatocellular carcinoma (HCC)[J]. J Clin Oncol, 39(3 suppl): 335.
[27] SHI Y H, JI Y, LIU W R, et al. A phase Ⅰb/Ⅱ, open-label study evaluating the efficacy and safety of Toripalimab injection (JS001) or combination with Lenvatinib as a neoadjuvant therapy for patients with resectable hepatocellular carcinoma[J]. J Clin Oncol, 2020, 38(6 suppl): TPS272-TPS272.
[28] PINATO D J, CORTELLINI A, SUKUMARAN A, et al.PRIME-HCC: phase Ⅰb study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma[J]. BMC Cancer, 2021, 21(1): 301.
[29] Kaseb A, Cao H S T, Abugabal Y I, et al. Final results of a randomized, open label, perioperative phaseⅡstudy evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC[J]. J Clin Oncol, 2020, 38(15 suppl): 4599.
[30] 周俭, 肖永胜, 李辉. 初始不可切除肝癌转化治疗主要模式及评价[J]. 中国实用外科杂志, 2021, 41(3): 280-284.
[31] WANG K, GUO W X, CHEN M S, et al.Multimodality Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Large-Scale, Multicenter, Propensity Mathching Score Analysis[J]. Medicine (Baltimore), 2016, 95(11): e3015.
[32] 孙惠川. 不可切除和中晚期肝癌的转化切除[J]. 腹部外科, 2021, 34(2): 85-87.
[33] XIE D Y, REN Z G, ZHOU J, et al.2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights[J]. Hepatobiliary Surg Nutr, 2020, 9(4): 452-463.
[34] 朱继业, 李照. 中晚期肝癌的转化手术切除[J]. 腹部外科, 2020, 33(2): 105-108.
[35] 向邦德, 黎乐群. 中晚期肝癌降期手术策略及展望[J]. 中国癌症防治杂志, 2019, 11(5): 359-362.
[36] 袁响林. 中晚期原发性肝癌的降期转化治疗[J]. 临床肝胆病杂志, 2020, 36(2): 267-271.
[37] ORLACCHIO A, CHEGAI F, MEROLLA S, et al.Downstaging disease in patients with hepatocellular carcinoma outside up-to-seven criteria: Strategies using degradable starch microspheres transcatheter arterial chemo-embolization[J]. World J Hepatol, 2015, 7(12): 1694-1700.
[38] LYU N, KONG Y, MU L, et al.Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 60-69.
[39] FAN J, TANG Z Y, YU Y Q, et al.Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma[J]. Dig Surg, 1998, 15(6): 674-678.
[40] GOTO Y, HISAKA T, SAKAI H, et al.Salvage Surgery for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Downstaged by Hepatic Arterial Infusion Chemotherapy[J]. Anticancer Res, 2020, 40(8): 4773-4777.
[41] YOON S M, RYOO B Y, LEE S J, et al.Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial[J]. JAMA Oncol, 2018, 4(5): 661-669.
[42] SHUI Y, YU W, REN X, et al.Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis[J]. Radiat Oncol, 2018, 13(1): 188.
[43] SUN H C, ZHU X D, HUANG C, et al.Combination therapy with lenvatinib and anti-PD-1 antibodies for unresectable or advanced hepatocellular carcinoma: A real-world study[J]. J Clin Oncol, 2020, 38(15 suppl): e16610.
[44] SUN H C, ZHU X D, HUANG C, et al.Initially unresectable hepatocellular carcinoma treated by combination therapy of tyrosine kinase inhibitor and anti-PD-1 antibody followed by resection[J]. J Clin Oncol, 2020, 38(15 suppl): e16690.
[45] ZHANG W W, HU B Y, HAN J, et al.A real-world study of PD-1 inhibitors combined with TKIs for HCC with major vascular invasion as the conversion therapy: A prospective, non-randomized, open-label cohort study[J]. Ann Oncol, 2020, 31(6 suppl): 174.
[46] HE M K, LIANG R B, ZHAO Y, et al.Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma[J]. Ther Adv Med Oncol, 2021, 13: 17588359211002720.
[47] HE M K, LI Q J, ZOU R H, et al.Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial[J]. JAMA Oncol, 2019, 5(7): 953-960.
[48] 李川江, 周杰. 肝细胞肝癌经肝动脉化疗栓塞联合索拉非尼降期后二期切除的初步报告[J]. 腹部外科, 2017, 30(4): 295-298, 301.
[49] HE M K, ZOU R H, LI Q J, et al.PhaseⅡStudy of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis[J]. Cardiovasc Intervent Radiol, 2018, 41(5): 734-743.
[50] ZHANG T, ZHANG J L, ZHANG X H, et al.Triple combination therapy comprising angiogenesis inhibitors, anti-PD-1 antibodies, and hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma[J]. J Clin Oncol, 2021, 39(15 suppl): e16124.
[51] CAI L, LI H, GUO J, et al.Drug-eluting bead transarterial chemoembolization is an effective downstaging option for subsequent radical treatments in patients with hepatocellular carcinoma: A cohort study[J]. Clin Res Hepatol Gastroenterol, 2021, 45(4): 101535.
[52] 海峡两岸医药卫生交流协会肿瘤防治专家委员会. 肝癌肝切除围手术期管理中国专家共识(2021年版)[J]. 中华医学信息导报, 2021, 36(8): 10. |
